Preliminary Results for the year ended 31 March 2020
20 July 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2020.
Further positive data in retinal clinical trial
Further long-term data demonstrate continuing, clinically meaningful efficacy at all time-points measured out to 18 months post-treatment
ReNeuron signs new exosome research collaboration
25 June 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a new research evaluation agreement with a major US biotechnology company in connection with the use of the Company’s proprietary exosomes for the delivery of novel gene silencing therapeutics.
June 2020 – Proactive Investors: ReNeuron’s Michael Hunt explains new emphasis on its retinal and exosome technology programmes
Regulatory approvals and programme update
17 June 2020: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programmes.
June 2020 – Proactive Investors: One2One Virtual Event
11 June 2020: ReNeuron Group’s (LON:RENE) Michael Hunt pitches the company to investors at the Proactive One2One Virtual Event. The company’s a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
May 2020 – Proactive Investors: ReNeuron’s Michael Hunt talks new potential for its CTX therapy in treating Huntington’s disease
ReNeuron’s CTX cell line shows further potential
Newly published positive efficacy data in an accepted model of Huntington’s disease
Exosome Research Collaboration
07 April 2020: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company’s proprietary exosomes to deliver novel therapeutics.